Cost-effectiveness of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma Meeting Abstract


Authors: Matasar, M.; Masaquel, A.; Rodrigo, H.; Launonen, A.; Ng, C.; Wang, R.; Fox, D.; Hossain, F.; Li, J.; Roth, J. A.; Burke, J. M.
Abstract Title: Cost-effectiveness of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
Meeting Title: 10th Annual Meeting of the Society of Hematologic Oncology (SOHO)
Keywords: cost-effectiveness; diffuse large b-cell lymphoma; vedotin; polatuzumab; abcl
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 22
Issue: Suppl. 2
Meeting Dates: 2022 Sep 28-Oct 1
Meeting Location: Houston, TX
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2022-10-01
Start Page: S359
End Page: S360
Language: English
ACCESSION: WOS:000897948100379
PROVIDER: wos
DOI: 10.1016/s2152-2650(22)01500-2
Notes: Meeting Abstract: ABCL-101 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Matthew J Matasar
    289 Matasar